GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR
Clinical trials for GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR explained in plain language.
Never miss a new study
Get alerted when new GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR trials appear
Sign up with your email to follow new studies for GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New radioactive drug targets Hard-to-Treat tumors in early trial
Disease control Recruiting nowThis early-phase study tests a new radioactive drug called RYZ401 in people with neuroendocrine tumors and other solid tumors that have a specific marker (somatostatin receptors). The main goals are to find the safest dose and schedule, and to see if the drug can shrink tumors or…
Matched conditions: GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR
Phase: PHASE1 • Sponsor: RayzeBio, Inc. • Aim: Disease control
Last updated May 01, 2026 15:38 UTC
-
Radioactive drug before and after surgery may improve outcomes for rare gut cancers
Disease control Recruiting nowThis early-phase study tests whether giving a radioactive drug (Lutathera) both before and after surgery is safe and feasible for people with metastatic neuroendocrine tumors of the gut or pancreas. About 10 adults with slow-growing tumors that have spread to lymph nodes or liver…
Matched conditions: GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR
Phase: PHASE1 • Sponsor: Stanford University • Aim: Disease control
Last updated May 01, 2026 15:32 UTC
-
New study tracks PRRT effects on neuroendocrine tumors
Disease control Recruiting nowThis study is gathering information on how well peptide receptor radionuclide therapy (PRRT) works for people with neuroendocrine tumors that started in the stomach, intestines, or pancreas. Researchers will track patient details, tumor changes, survival, and side effects. The go…
Matched conditions: GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR
Sponsor: Methodist Health System • Aim: Disease control
Last updated Apr 30, 2026 15:48 UTC
-
New hope for rare cancers: immunotherapy combo trial launches
Disease control Recruiting nowThis study tests a combination of two immunotherapy drugs (domvanalimab and zimberelimab) in people with five types of rare advanced cancers that have not responded to standard treatment. The goal is to see if this treatment can control the cancer for at least 24 weeks. About 154…
Matched conditions: GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR
Phase: PHASE2 • Sponsor: Hospices Civils de Lyon • Aim: Disease control
Last updated Apr 29, 2026 15:14 UTC
-
Could diet impact Slow-Growing tumor outcomes? new study investigates
Knowledge-focused Recruiting nowThis study looks at whether nutritional status is linked to better outcomes in adults with slow-growing digestive neuroendocrine tumors. Researchers will check for malnutrition in 100 participants and see how it relates to their health. The goal is to find if improving nutrition …
Matched conditions: GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR
Sponsor: University Hospital, Strasbourg, France • Aim: Knowledge-focused
Last updated May 01, 2026 15:36 UTC
-
New study aims to predict which patients benefit from targeted radiation therapy
Knowledge-focused Recruiting nowThis study will follow 80 people with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) who are receiving peptide receptor radionuclide therapy (PRRT). Researchers will use advanced PET-MRI scans and genetic profiling before, during, and after treatment to find pat…
Matched conditions: GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR
Phase: NA • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated May 01, 2026 15:25 UTC